Weight-loss and diabetes drugs
Ozempic does not raise blood pressure. On average it lowers it, usually by a few mmHg of systolic, and the drop tracks how much weight you lose. What semaglutide does raise is your resting heart rate, typically by two to four beats per minute, and that is where the confusion starts: your monitor prints a pulse number next to the pressure numbers, the pulse has gone up, and it reads like the medicine pushed everything up. It did not. Take two weeks of readings, work out your mean arterial pressure before and after, and you will normally see the pressure sitting lower and the pulse sitting higher.
The short answer for every drug in this family
Semaglutide (sold as Ozempic, Wegovy and Rybelsus) and tirzepatide (Mounjaro and Zepbound) both belong to the incretin family, and hypertension is not a listed adverse reaction for any of them. Pooled trial data points the other way. Across the large weight-loss and diabetes programs, systolic pressure fell by roughly three to eight mmHg depending on the drug, the dose and how much weight the participants shed, with diastolic falling a smaller amount, often one to three mmHg. Tirzepatide tends to produce the bigger drop because it tends to produce the bigger weight loss.
Two mmHg of that may be a direct kidney effect. The rest follows the scale. Losing body weight lowers blood pressure whether you do it with a drug, with surgery or with a food diary, and these medicines are simply an unusually effective way of doing it. The corollary matters just as much: when people stop and the weight comes back, the pressure comes back with it.
The heart rate rise is real, consistent and separate. It shows up in almost every trial of every GLP-1 receptor agonist, it appears within weeks, and it persists for as long as you take the drug. Nobody has fully explained it. The leading theory is a direct action on the sinoatrial node, where the heart’s pacemaker cells carry GLP-1 receptors. A faster pulse at rest is not the same problem as a higher pressure, and the difference between pulse and pressure is the single most useful thing to understand before you interpret anything your cuff tells you on this medication.
The real danger here is pressure falling too far, not rising
Vomiting and diarrhea are common when a dose goes up. Lose enough fluid and your circulating volume drops, which can send blood pressure down hard. That risk multiplies if you take a water tablet, because a diuretic already works by reducing your circulating volume, and it multiplies again if you take an ACE inhibitor or an ARB on top, because that combination leaves the kidney with very little defense against a sudden drop in perfusion. Acute kidney injury from dehydration is one of the better documented safety signals in this drug class. If you cannot keep fluids down for a day, call your prescriber rather than waiting it out.
Emergency care immediately, not a phone call in the morning, for a reading above 180 systolic or above 120 diastolic, or for chest pain, breathlessness, one-sided weakness, slurred speech, vision loss or a sudden severe headache. Those signs outrank anything on this page.
Quick reference: what each drug does to the number
Read the direction column as a population average and never as a forecast for you. Trial averages hide enormous individual spread, and a drug that lowers pressure by five mmHg across a thousand people has certainly raised it in a few of them.
| Drug | Brand names | Effect on blood pressure | Effect on heart rate |
|---|---|---|---|
| Semaglutide | Ozempic, Wegovy, Rybelsus | Down, roughly 3 to 6 mmHg systolic at weight-loss doses | Up, about 3 to 4 bpm |
| Tirzepatide | Mounjaro, Zepbound | Down, roughly 5 to 8 mmHg systolic in the obesity trials | Up, about 2 to 4 bpm |
| Liraglutide | Victoza, Saxenda | Down, roughly 2 to 4 mmHg systolic | Up, about 2 to 3 bpm |
| Dulaglutide | Trulicity | Down, small and less consistent | Up, about 2 to 4 bpm |
| Exenatide | Byetta, Bydureon | Down, small | Up, modest |
| Empagliflozin | Jardiance | Down, roughly 3 to 5 mmHg systolic | Neutral or slightly down |
| Dapagliflozin | Farxiga | Down, similar to empagliflozin | Neutral |
| Metformin | Glucophage, Fortamet | Neutral to very slightly down | Neutral |
| Sitagliptin | Januvia | Neutral, perhaps 1 to 2 mmHg down | Neutral |
| Glipizide, glimepiride | Glucotrol, Amaryl | Neutral | Neutral |
| Pioglitazone | Actos | Slightly down, but causes fluid retention and edema | Neutral |
| Insulin | many | Neutral short term; weight gain pushes it up over years | Neutral |
| Phentermine | Adipex-P, Lomaira | Up in many people; a stimulant effect | Up, sometimes markedly |
| Phentermine with topiramate | Qsymia | Mixed; weight loss pulls down, the stimulant pushes up | Up |
| Naltrexone with bupropion | Contrave | Small rise reported, mostly early | Up slightly |
| Orlistat | Xenical, Alli | Down slightly, entirely via weight | Neutral |
Two things stand out. Every incretin drug in that list moves pressure down and pulse up at the same time, which is an unusual combination and the reason so many people misread their monitor. And the only entries that push pressure up are the stimulant-based appetite suppressants, which work through a completely different mechanism. If you want a baseline for judging any of these shifts, the standard blood pressure ranges are set out separately, and whether a five mmHg fall matters to you depends on whether it takes you from 140/90 territory down to the 130/80 band or merely shuffles you around inside the normal range.
Blood pressure medicines are a separate topic
None of the drugs above are prescribed to treat hypertension. If you want the classes that are, the common blood pressure medications are covered in their own guide, along with what each class does and why one gets chosen over another.
Heart rate is not blood pressure, and this is where the myth comes from
Almost every home monitor shows three numbers. Systolic on top, diastolic below it, and a small heart symbol with a pulse figure beside it. Four months into semaglutide, a person who used to see 62 bpm now sees 71 bpm. Their brain files that as “my blood pressure is up on this drug” and the story spreads. The pressure numbers, in the same reading, have usually come down.
Pressure is force against the artery wall. Pulse is how many times a minute your heart contracts. They are related the way speed and engine revs are related in a car: connected, but you can raise one while the other falls, and a lower gear proves it. Your heart can beat faster and push less volume per beat, which is roughly what happens here. There is a whole separate question about whether a low pressure implies a low pulse, and the answer is no in both directions.
The rise itself is small and well characterized. Semaglutide adds around three to four beats per minute on average at the higher doses. Tirzepatide sits in a similar range. Liraglutide adds two or three. In a minority of people the increase is larger, ten beats or more, and that group is worth flagging to a doctor, particularly if there is a history of arrhythmia. For everyone else a resting pulse that has moved from the low sixties to the low seventies sits inside the normal band and has not, in the large outcome trials, translated into harm.
A practical test: take your reading, note the pulse, then compare it against a reading from the same chair at the same hour before you started the drug. If the pulse has risen and the pressure has fallen, that is the expected pattern for this drug class. If both have risen, something else is going on, and a decongestant, a new painkiller, alcohol or poor sleep is a more likely explanation than the injection.
That last point deserves emphasis because the confounders are everywhere. Ibuprofen and the other NSAIDs blunt most blood pressure medication and push readings up by a few mmHg on their own. Cold and flu products containing pseudoephedrine or phenylephrine raise pressure by design. People starting a GLP-1 are often changing several things at once, including diet, exercise and other prescriptions, and the injection ends up carrying the blame for all of it.
How far the number falls, with real arithmetic
Averages from trials are a poor guide to what one person sees, so here are three scenarios built from typical trial-sized changes. The point of running the mean arterial pressure alongside the raw numbers is that MAP tells you what your organs are perfused at, and it moves less dramatically than systolic does, which stops you over-reading a single good day.
MAP = diastolic + (systolic - diastolic) / 3Pulse pressure = systolic - diastolicCase one. A 54-year-old with type 2 diabetes and stage 2 hypertension starts semaglutide. Baseline home average 146/90, pulse 68. Twelve months later, 22 pounds lighter, the average reads 136/84, pulse 74. Baseline MAP was 90 + (146-90)/3, which is 90 + 18.7, so 108.7 mmHg. New MAP is 84 + (136-84)/3, which is 84 + 17.3, so 101.3 mmHg. Seven mmHg of mean pressure gone, pulse pressure down from 56 to 52, and the pulse up six beats. That reading has moved out of stage 2 and into stage 1 under the US categories, which is the kind of shift that changes a treatment conversation.
Case two. A 41-year-old with no diabetes takes tirzepatide for obesity. Baseline 132/86, pulse 72. Nine months and 18 percent body weight later, 121/78, pulse 78. Baseline MAP 86 + 15.3 = 101.3. New MAP 78 + 14.3 = 92.3. Nine mmHg of mean pressure, and the reading has crossed from stage 1 into the elevated band. Under the European and UK thresholds, which still start hypertension at 140/90, neither reading was ever labeled hypertensive, so the same person gets a different diagnosis depending on which side of the Atlantic they live. That is a real difference in practice and it is part of why 120/80 is a less reassuring number than people assume.
Case three, the one that scares people. A 63-year-old on lisinopril and hydrochlorothiazide starts a GLP-1, gets three days of vomiting after a dose increase, and records 94/58 with a pulse of 96. MAP is 58 + (94-58)/3, which is 58 + 12, so 70 mmHg. That sits barely above the rough 60 mmHg floor for organ perfusion, the pulse is racing to compensate, and this is a call-your-doctor-today reading rather than a wait-and-see one. Volume depletion, not the drug’s pharmacology, produced it.
Two of those cases are the drug working as intended on a body that is getting smaller. The third is a fluid problem wearing the drug’s clothes. Telling them apart is most of the skill here, and a mean pressure calculated from your own readings makes the distinction obvious faster than staring at systolic alone.
Those bands are a rough guide for an adult with no unusual circulation, and a MAP of 72 in a small, fit 25-year-old means something quite different from the same figure in a 78-year-old with stiff arteries. The threshold at which a low reading becomes a problem has more to do with symptoms than with any single cutoff.
Why the pressure drops at all
The dominant mechanism is uninteresting and unarguable: you weigh less. Every kilogram of fat tissue needs perfusing, and shedding it reduces cardiac output, reduces sympathetic nervous system activity, reduces the leptin-driven pressure signal and improves how well your arteries relax. The rough historical rule of thumb from lifestyle trials is about one mmHg of systolic per kilogram lost, which lines up reasonably well with what the semaglutide and tirzepatide programs report. A person who drops 15 kg and sees systolic fall seven or eight mmHg is behaving exactly like a person who dropped 15 kg any other way.
There is probably a smaller direct effect on top of that. GLP-1 receptors sit in the kidney, and activating them appears to reduce sodium reabsorption in the proximal tubule, so you excrete a bit more salt. That is the same broad lever that makes dietary sodium matter so much, approached from the other end. Some analyses find blood pressure starting to fall earlier than the weight curve would predict, which supports a direct component. The honest position is that the size of that direct effect is not settled, the studies designed to separate it from weight loss are small, and anyone quoting a precise split is guessing.
A third pathway gets less attention than it deserves. Obstructive sleep apnea drives hypertension hard, and it improves substantially with weight loss. Tirzepatide has been studied specifically in moderate to severe sleep apnea in adults with obesity and produced large reductions in apnea events, which is now a licensed use in the United States. If your night-time breathing improves, your overnight pressure improves, and overnight pressure is a stronger predictor of cardiovascular risk than daytime pressure. That is one route by which sleep quality feeds into blood pressure that a daytime cuff will never show you directly.
What none of this makes these drugs is antihypertensives. They are not licensed to treat high blood pressure, they are not prescribed for it, and a five mmHg average is a fraction of what a standard first-line agent delivers. An ACE inhibitor like lisinopril or an ARB like losartan will typically move systolic by ten to fifteen mmHg. The GLP-1 effect is a welcome side benefit sitting alongside the main event.
What the SELECT trial showed, and what it did not
SELECT is the study people mean when they say these drugs protect your heart. It enrolled roughly 17,600 adults who had established cardiovascular disease and a BMI of 27 or above, but no diabetes, and randomized them to weekly semaglutide at the weight-loss dose or placebo on top of whatever else they were taking. Over an average of a little more than three years, the group on semaglutide had about a 20 percent lower rate of the combined endpoint of cardiovascular death, non-fatal heart attack and non-fatal stroke. That is a large trial with a hard outcome, and it is the reason the Wegovy label in the United States now carries a cardiovascular risk indication.
Blood pressure fell in that trial too, by a few mmHg, and so did weight, waist circumference, inflammatory markers and lipids. What the trial cannot tell you is which of those changes did the work. The benefit appeared earlier than the weight curve alone would predict, which has led to serious speculation about direct anti-inflammatory or vascular effects. That remains speculation. Some boundaries are worth drawing around the result, because the marketing rarely draws them:
Everyone in SELECT already had cardiovascular disease. The trial says nothing about a 35-year-old with a BMI of 31 and a clean heart. Absolute benefit scales with baseline risk, and in a low-risk person the same relative reduction is worth far less.
Nobody in SELECT had diabetes. The diabetes evidence comes from separate trials such as SUSTAIN-6 and LEADER, which also showed cardiovascular benefit, though the drivers differed between them.
It ran for a bit over three years. These are drugs many people expect to take for decades, and three years is not decades.
Cardiovascular events fell. The trial was not powered to prove that blood pressure reduction specifically caused that, and the pressure change was small enough that it can only be part of the story.
The blunt summary: the cardiovascular benefit in that population is well established, the blood pressure reduction is real but modest, and the causal chain between them is inferred rather than proven. This class is hyped to a degree that makes calibration difficult. It is a good drug family with real outcome data, and it is far short of the metabolic cure the headlines suggest.
When the pressure drops too far
Low blood pressure is by far the more likely complaint on these drugs, and it has three separate causes that need untangling because the fix differs for each.
Fluid loss from the gut
Nausea, vomiting and diarrhea are the most common side effects in every trial, and they cluster around dose increases. Two days of vomiting can strip enough volume to knock ten or fifteen mmHg off your systolic. Add a diuretic and the drop compounds. Add an ACE inhibitor or an ARB as well and the kidney loses its main compensation mechanism, which is how the acute kidney injury cases in the post-marketing reports arise. This is the scenario to take seriously.
Eating and drinking far less
These drugs work by suppressing appetite, and appetite suppression takes thirst with it more often than people expect. Someone who used to drink two liters a day without thinking now drinks half that. Combine reduced fluid intake with reduced salt intake, because you are eating less of everything, and you have a slow, unspectacular volume depletion that shows up as lightheadedness on standing rather than as any dramatic reading. Hydration and blood pressure pull in a direction people find counterintuitive here.
Blood pressure medication that is now too strong
This one is a success, not a side effect. You were prescribed two antihypertensives for a body that weighed 240 pounds. At 195 pounds the same doses are doing more than they need to, and your readings drift low. The symptom is postural dizziness, sometimes with fatigue. It resolves when a doctor adjusts the regimen. It does not resolve, and can get worse, if you simply carry on.
The symptoms overlap enough that people misattribute them constantly. Lightheadedness on standing, blurring vision for a second or two when you get out of a chair, unusual fatigue, and in bad cases fainting. Those are the recognizable signs of low blood pressure, and if you get them, sit down before you check, because measuring while you are swaying gives you a number you cannot use. Readings in the 90/60 region with symptoms need a same-week call. Readings around 100/70 with no symptoms are usually fine and sometimes just what a lighter body runs at.
There is an important asymmetry in how people treat these two problems. A person whose pressure creeps up gets anxious and calls the office. A person whose pressure drifts down feels vaguely tired, assumes it is the diet, and says nothing for four months. The second person is the one more likely to fall and break a hip. Dizziness deserves the same attention as a high reading, and dizziness from blood pressure medication is common enough to have its own literature.
Taking a GLP-1 alongside blood pressure medication
There is no pharmacokinetic clash between semaglutide or tirzepatide and any of the standard antihypertensive classes. No enzyme competition worth worrying about, no contraindication, no need to separate the doses. Millions of people take a GLP-1 with an ACE inhibitor, an ARB, a calcium channel blocker such as amlodipine, a thiazide or a beta blocker like metoprolol, and that combination is entirely routine.
The interaction that does exist is additive rather than chemical. Two things lowering your pressure at once will lower it more than one, and as your weight falls the antihypertensive regimen that was correctly sized in January can be oversized by September. Deprescribing is a normal and expected part of a successful weight loss course. It is also, without exception, a decision for the person who wrote the prescription. Halving your own dose because your readings look good is how people end up in the ER with a rebound spike, and several classes, beta blockers and clonidine especially, produce a genuinely dangerous rebound when they are stopped abruptly. Stopping blood pressure tablets is one of the few areas of medicine where the do-it-yourself version has an obvious body count.
One slower interaction is worth planning for. Semaglutide and tirzepatide delay gastric emptying, which is part of how they make you feel full. In theory that could change how quickly an oral tablet is absorbed. In practice the studies on this have not found clinically meaningful shifts for common blood pressure medications, and the effect on gastric emptying weakens over months of treatment. The exception flagged on the labels is oral contraceptives with tirzepatide, which is a real caution even though it has nothing to do with pressure.
Additive logic covers everything else in the cabinet that lowers pressure too. Tadalafil and the other ED drugs take a few mmHg off on their own, and taking any of them with a nitrate is an absolute contraindication because the two together can collapse blood pressure to a life-threatening level. Weight loss puts a lot of men back in the market for those prescriptions, so the combination comes up more often in this group than you might guess.
Bring a log, not an anecdote. Four weeks of home readings, taken the same way at the same times, with the pulse written down beside each one, tells a doctor in thirty seconds what a description of how you have been feeling cannot convey in ten minutes. Two readings a day, morning and evening, is enough. Consistency in when you measure matters more than the total number of readings.
Take the timing question to the same person. Whether your antihypertensive is better at night or in the morning is a live argument with trial evidence pointing both ways, and it interacts with when you inject and when your nausea peaks. There is a fuller treatment of what time of day to take blood pressure medication elsewhere on the site, and the summary is that consistency beats cleverness.
Metformin, Jardiance and the rest of the diabetes shelf
Metformin does not raise your blood pressure. It is the most prescribed diabetes drug on earth, it has been in use since the 1950s, and hypertension has never been among its recognized effects. Meta-analyses of metformin trials find either no change in pressure or a very small reduction of a mmHg or two, and the reduction is inconsistent enough that treating it as real would be overreach. Its side effects live in the gut and, at the rare extreme, in lactic acidosis when kidney function is poor.
Taking metformin with a blood pressure medicine is unremarkable. There is no direct interaction with ACE inhibitors, ARBs, calcium channel blockers, beta blockers or thiazides, and the combination is one of the most common prescription pairings in general practice. The one link between them runs through your kidneys. Metformin is cleared renally, so anything that damages kidney function raises the level of metformin in your blood, and the combination of an ACE inhibitor or ARB plus a diuretic plus an NSAID during an episode of dehydration is the classic recipe for exactly that. That is a hydration and NSAID problem, and it is another reason regular ibuprofen use deserves more scrutiny than it usually gets.
The SGLT2 inhibitors are the diabetes class that genuinely does lower blood pressure. Empagliflozin, sold as Jardiance, and dapagliflozin, sold as Farxiga, make you excrete glucose in your urine and drag sodium and water along with it. The result is a mild diuretic effect and a systolic reduction of roughly three to five mmHg that shows up consistently across trials. They also have strong outcome data in heart failure and chronic kidney disease that has nothing to do with glucose. Because they act partly as diuretics, they carry the same volume-depletion caution: combining one with a loop diuretic in a hot summer, in an older person, is how people end up dizzy.
The rest of the shelf is quiet. DPP-4 inhibitors such as sitagliptin are close to neutral. Sulfonylureas do nothing to pressure directly, though the weight gain they cause pushes the wrong way over years. Pioglitazone slightly lowers pressure but causes fluid retention and ankle swelling, which confuses people who assume swelling means high pressure. Insulin is neutral early and, through weight gain, unhelpful late. That pattern repeats across diabetes care: what a drug does to your weight usually outweighs what it does to your arteries.
Glucose itself is a separate lever. Chronically high blood sugar stiffens arteries and damages the endothelium, which raises systolic pressure over years. Getting glucose under control helps pressure eventually, but slowly, and never fast enough to explain a change you notice this month.
Phentermine goes the other way, and that contrast is the point
Phentermine is a weight loss drug that does raise blood pressure. It is a sympathomimetic amine, chemically related to amphetamine, and it works by driving noradrenaline release to suppress appetite. That same mechanism speeds the heart and constricts arteries. The US label lists uncontrolled hypertension among the contraindications, along with advanced arteriosclerosis and cardiovascular disease, and prescribers are expected to check pressure before starting and monitor it after.
The picture in trials is messier than the pharmacology suggests, because phentermine also produces weight loss and weight loss lowers pressure. Net average change across a study population can come out neutral or even slightly negative. That average conceals two opposing effects, and the individual who gets a fifteen mmHg rise is invisible inside it. Treat phentermine as a drug that raises pressure in a meaningful minority of people and monitor accordingly. The combination product with topiramate, sold as Qsymia, behaves similarly, with topiramate contributing nothing much either way to pressure.
People search for how to lower blood pressure while taking phentermine, and the answer has an uncomfortable first step. If the drug is pushing your readings up and they stay up, the correct move is a conversation about whether you should be on it at all, not a workaround. Beyond that the levers are the ordinary ones: cutting sodium, alcohol, caffeine stacked on top of a stimulant, and sleep, which phentermine wrecks in a lot of people and which feeds straight back into pressure. There is a full guide to the most effective ways to lower blood pressure and a separate one on doing it without medication, and both apply here.
The history of this drug category is worth a moment. Fenfluramine with phentermine, the fen-phen combination, was withdrawn in 1997 after valve damage emerged. Sibutramine was withdrawn in 2010 after a large trial found excess cardiovascular events, and its mechanism was closely related to phentermine’s. Stimulant appetite suppressants have a poor safety record over decades of use, and the incretins are notable partly because they are the first weight loss drugs to show cardiovascular benefit rather than harm. That comparison is the strongest argument in their favor.
Stacking stimulants is where this turns dangerous
Phentermine plus a decongestant, plus high-dose caffeine, plus a pre-workout supplement is a combination that lands people in emergency departments with pressures above 180. Each item alone is modest. Together they are not. The same warning applies to any stimulant, including the ADHD medicines discussed under psychiatric drugs and blood pressure, and to the pseudoephedrine hiding in multi-symptom cold products.
How to track this properly over a course of treatment
Almost every argument about whether a drug changed your blood pressure is settled by whether you have a baseline. Start one before your first injection if you possibly can, and if you have already started, begin today and treat the first week as your reference point.
Build a seven-day baseline
Two readings in the morning before food or coffee, two in the evening, for seven days, discarding day one entirely because first-day readings run high. Average what is left. That average is your number. A single reading is close to meaningless for this purpose, and the technique matters enough that getting the measurement right is worth reading before you start collecting data you will later rely on.
Write the pulse down every single time
This is the step people skip and the one that answers the question they came with. Your monitor already shows it. A column of pulse figures next to a column of pressures makes the pattern unmistakable within a month, and it lets you separate a drug effect from a bad night’s sleep.
Add weight, weekly, on the same scale
The pressure change on this drug class is largely a weight story, so the weight column is the explanation column. Weekly is enough. Daily weighing adds noise and anxiety without adding information.
Re-measure in the week after every dose increase
Dose escalations are when nausea and vomiting cluster, and therefore when volume depletion is most likely. Check morning and evening for the first five days after a step up, and add a standing reading taken one minute after you get to your feet. A fall of more than 20 systolic or 10 diastolic on standing is orthostatic hypotension and is worth reporting.
Re-baseline every three months
Repeat the seven-day protocol quarterly and compare averages. A year of treatment gives you four clean data points with a weight curve beside them, which beats anything a memory can supply in an appointment.
A word on equipment. An upper-arm cuff validated for clinical accuracy is the only sensible tool for this, and the question of which monitor to trust has a real answer. Wrist devices drift. Smartwatches cannot yet measure blood pressure in any way you should base a medication decision on, though they track resting heart rate well, and heart rate is the number that moves on this drug.
Fluid deserves its own line in the log. If you are eating a third less than you used to, you are drinking less water in your food and taking in less sodium, and both matter. Deliberately drinking to a target rather than to thirst is reasonable advice during the escalation phase, and the point at which hydration starts to affect your readings arrives earlier than people expect on an appetite suppressant.
What happens to your blood pressure when you stop
This is the part the enthusiasm skips over. When people come off semaglutide, weight comes back. The best evidence on this comes from the extension phase of the STEP 1 trial, where participants who stopped regained roughly two thirds of the weight they had lost within about a year. The cardiometabolic improvements went with it. Blood pressure, waist circumference and lipids all drifted back toward where they started.
That should not surprise anyone, given the mechanism. If the pressure fell because the weight fell, the pressure rises when the weight returns. Obesity behaves like a chronic condition that responds to treatment while treatment continues, in the same way hypertension itself does. You would not expect your pressure to stay down for years after stopping amlodipine.
The practical consequences are specific. If a doctor reduced your antihypertensive dose during weight loss, that reduction may need reversing when you stop, and it needs the same supervision going up as it did coming down. Your readings can climb over a period of months, quietly, and you will not feel it, because high blood pressure produces almost no symptoms until it is severe. Keep measuring for at least six months after your last injection. That is the window in which people stop paying attention and their numbers change most.
Supply shortages create the same situation involuntarily, and they have forced people off these drugs for months at a stretch. The things that hold weight steady without the injection are the unglamorous ones: regular aerobic exercise, protein and fiber that keep you full, sleep, and a diet built around the foods that lower pressure on their own. None of that matches the drug. All of it helps at the margin, and the margin is where relapses are won.
When to worry
Call emergency services now, without waiting to re-check, for a reading above 180 systolic or above 120 diastolic accompanied by chest pain, breathlessness, one-sided weakness, difficulty speaking, vision loss, confusion or a sudden severe headache. Those combinations are a hypertensive emergency and they are treated in hours. A reading that high with no symptoms is still urgent and warrants a same-day call.
Also get medical help the same day for any of these while on a GLP-1:
You cannot keep fluids down for 24 hours. Dehydration on top of a diuretic and an ACE inhibitor or ARB is the combination that damages kidneys, and it moves faster than people expect in hot weather or in anyone over 70.
You faint, or you come close to fainting, when standing up. A drop of more than 20 systolic on standing is a measurable finding a doctor can act on, and it usually means either volume depletion or antihypertensive doses that no longer match your body.
Your resting pulse has risen by more than about 15 beats per minute from your own baseline, or you are getting palpitations. The expected rise on this drug class is small, and a large one is a different conversation.
Severe abdominal pain radiating to your back, with or without vomiting. That is a pancreatitis presentation, it is rare, and it is on every label in this class.
Your systolic has climbed by 15 mmHg or more from your own baseline and stayed there across a full week of readings, with no obvious explanation such as a new NSAID, a decongestant, alcohol or a period of poor sleep.
None of those are reasons to stop the injection on your own initiative. They are reasons to get someone qualified to look at your log. The instinct to self-correct is understandable and it consistently makes things worse, both with these drugs and with the antihypertensives sitting beside them in the cabinet.
Common mistakes people make with this
Reading the pulse as the pressure
The single most common error in this whole territory. Your monitor shows both, one has gone up and the other has gone down, and the eye lands on the one that moved in the alarming direction. Write both columns down and the confusion resolves itself.
Comparing a morning reading to an evening one
Pressure follows a daily rhythm with a swing of ten mmHg or more between its low point and its peak. Comparing 8am in March to 9pm in July tells you about the clock. Same chair, same hour, same arm.
Adjusting an antihypertensive without asking
Readings improve, the reasoning seems sound, half a tablet gets skipped. Rebound hypertension after abrupt beta blocker or clonidine withdrawal is severe and sometimes lands people in hospital. This decision belongs to a prescriber every time.
Ignoring dizziness because weight loss is going well
Feeling faint when you stand is a finding, and it does not become less of one because the scale is cooperating. It usually means volume depletion, oversized antihypertensive doses, or both together.
Blaming the injection for an NSAID
Someone starts a GLP-1, takes ibuprofen for a knee, and sees pressure climb. The painkiller is the more likely culprit, and it also blunts whatever antihypertensive you are on.
Expecting it to replace a blood pressure medicine
A few mmHg is a bonus, and it is a small fraction of what a first-line agent does. These drugs treat weight and glucose. Hypertension has its own toolkit and its own thresholds.
Skipping fluids while skipping food
Appetite suppression suppresses thirst too. Two liters a day sounds like advice from a magazine until you have been dizzy on a staircase because your intake quietly halved.
Stopping the log after one good quarter
The interesting changes land at dose escalations, during illness and after discontinuation. A record that ends in month three misses every one of them.
If you want the arithmetic done for you rather than in your head, the mean arterial pressure calculator takes a systolic and diastolic pair and returns the figure, and it sits alongside the other health calculators on the site.
Questions people ask
Does Ozempic lower your blood pressure and cholesterol?
Both, modestly. Semaglutide trials report small systolic falls of a few points along with reductions in triglycerides and, less consistently, in LDL. The lipid changes are mostly a consequence of losing fat mass and improving insulin sensitivity, and they are nowhere near the size of what a statin delivers. If you have been prescribed one for cholesterol, treat this as an addition to it and not a replacement.
Can Ozempic cause low blood pressure?
Indirectly, yes. The drug has no direct hypotensive action, but heavy vomiting or diarrhea after a dose step-up can empty your tank fast, and the result looks like hypotension because it is hypotension. The other route is slower: your body shrinks, your existing pressure tablets become too strong for it, and readings drift low across a few months. Symptoms are the trigger for action in either case.
Does Mounjaro cause high blood pressure?
No. Tirzepatide, the ingredient in Mounjaro and Zepbound, showed some of the largest systolic reductions in the whole incretin class in its obesity trials, in the region of five to eight points. Hypertension is not listed as an adverse reaction. What Mounjaro does share with the rest of the family is the small resting heart rate increase, which is the thing people are usually noticing when they ask this.
Can Zepbound raise blood pressure?
Zepbound and Mounjaro contain the same molecule, so the answer is the same drug’s answer: pressure down on average, pulse up slightly. Zepbound carries an additional licensed use for obstructive sleep apnea in adults with obesity, and treating apnea tends to improve overnight pressure, so if anything the case for a downward push is stronger with this label than with the diabetes one.
Can you take Wegovy or Zepbound if you already have high blood pressure?
Hypertension is not a contraindication for either, and in fact people with high pressure are heavily represented in the trials that established these drugs. Your prescriber will want to know your current readings, what you take for them, and especially whether a diuretic is in the mix, since that changes how carefully the dehydration risk needs watching. Bring numbers to that appointment.
Does Wegovy raise blood pressure?
Wegovy is semaglutide at the higher weight-management dose, and its trials show the opposite: systolic falling by roughly five points on average, with the size of the fall tracking the size of the weight loss. The US label now includes a cardiovascular risk-reduction indication on the strength of a large outcome study. A rise on Wegovy points at something other than the drug.
Can I take a GLP-1 with my blood pressure medication?
Yes, and it is an extremely common combination. No dose separation is needed and there is no chemical clash with any of the usual classes. The thing to watch for is the additive effect as your weight comes down, which can eventually make your antihypertensive regimen stronger than you need. That is a good problem, and it is one your doctor solves, never you.
Can metformin raise your blood pressure?
It does not. Seventy years of use have produced no signal in that direction, and pooled analyses land on either no effect or a reduction too small to rely on. People who see their pressure rise after starting metformin have almost always changed something else at the same time, and undiagnosed hypertension is extremely common in newly diagnosed type 2 diabetes anyway, so the timing often reflects when someone first started measuring.
Can you take blood pressure medicine with metformin?
Yes. This pairing is one of the most frequently written prescriptions in primary care and there is no interaction to schedule around. The only caution worth carrying is that metformin leaves the body through your kidneys, so during a stomach bug or a spell of vomiting, when your kidneys are under strain from dehydration plus your pressure tablets, doctors often advise pausing it temporarily. That advice comes from them and applies to the illness, not to normal days.
Does Jardiance affect blood pressure?
Yes, downward and fairly reliably. Empagliflozin makes your kidneys dump glucose into your urine, and sodium and water follow, so it behaves partly like a gentle water tablet. Expect something in the region of three to five systolic points. Combining it with a loop diuretic in an older person during hot weather is the situation where that mild effect becomes a dizziness problem.
Does phentermine cause high blood pressure?
It can, and its label reflects that with a contraindication in uncontrolled hypertension. Phentermine drives noradrenaline release, which narrows arteries and speeds the heart. Study averages sometimes look neutral because the weight loss pulls in the opposite direction, but an average is a poor guide when two forces cancel, and the people who get a substantial rise disappear inside it. Anyone taking it needs their readings checked, not assumed.
How do I lower my blood pressure while taking phentermine?
Start by asking whether you should still be on it, because a drug that is pushing your readings up while treating something non-urgent is a poor trade. If your doctor keeps you on it, strip out the things stacking on top: caffeine, energy drinks, pre-workout powders, decongestants and alcohol. Fix sleep, which phentermine damages in many people. Cut sodium hard. Those measures work on top of a stimulant, though they rarely fully cancel it.
Does tirzepatide or semaglutide cause low blood pressure?
Neither is a hypotensive drug in its own right, and the label for neither lists hypotension as a direct effect. Low readings on either come through dehydration from gastrointestinal side effects, through reduced eating and drinking, or through pressure medication that has outgrown its usefulness as your body changed. All three are manageable once identified, and identifying them requires a log.
My pulse went up on Ozempic. Should I be worried?
A rise of two to four beats per minute at rest is the documented, expected finding for this drug family and has not been linked to harm in the large outcome trials. A rise of fifteen or more from your own usual figure, or palpitations, or a racing pulse alongside dizziness, is a different picture and deserves a call. Keep the pulse column in your log so you can tell a small drift from a real jump.
The summary worth keeping
Ozempic does not raise blood pressure. The same holds for Wegovy, Mounjaro, Zepbound, Trulicity and the rest of the incretin family, and pooled trial data has them lowering systolic pressure by a few mmHg, chiefly because they make you lighter. Resting heart rate goes up by a small amount on all of them, which is the thing people are seeing when they think their pressure has climbed. Keep both columns in your log, average across seven days rather than reacting to single readings, and run the pair through the mean arterial pressure calculator so you are comparing a stable figure over time.
The risk in this territory runs downward. Vomiting, diarrhea, reduced fluid intake and antihypertensive doses that were sized for a heavier body can combine into readings that are genuinely too low, and the combination of dehydration with a diuretic plus an ACE inhibitor or ARB is the one that damages kidneys. Watch for dizziness on standing with the same seriousness you would give to a high reading. Every medication change, in either direction, goes through the person who prescribed it.
Phentermine is the counterexample that makes the pattern clear, since it raises pressure through a stimulant mechanism and is avoided in uncontrolled hypertension. Metformin is neutral. The SGLT2 inhibitors lower pressure mildly through a diuretic-like action. And the cardiovascular benefit shown in the large semaglutide outcome trial is real, though it was measured in people who already had heart disease and over a span of a few years, so the picture for everyone else is still being filled in. More of the story on blood pressure and the things that change it is collected across the rest of the site, including the reading-by-reading guides that tell you what your own numbers mean.
Related reading
Medical disclaimer
This article is general health information and is not medical advice, a diagnosis or a treatment plan. It contains no dosing guidance and none should be inferred from it. Do not start, stop, switch or adjust any prescription, including semaglutide, tirzepatide, metformin or any blood pressure medication, on the basis of anything written here. Those decisions belong to a doctor or pharmacist who knows your kidney function, your other conditions, your age and everything else you take.
Seek emergency care immediately for a reading above 180 systolic or above 120 diastolic, or for chest pain, breathlessness, one-sided weakness, difficulty speaking, vision loss, confusion or a sudden severe headache.
Understanding blood pressure readings, including the current US category thresholds.
About high blood pressure, with background on risk factors and monitoring.
